Psychostimulant effect of levodopa: Reversing sensitisation is possible

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 1, 2013, Pages 18-22

  Castrioto, Anna ^a,b,c   Kistner, Andrea ^a,b   Klinger, Hélène ^d,e   Lhommée, Eugénie ^a,b   Schmitt, Emmanuelle ^a,b   Fraix, Valérie ^a,b   Chabardès, Stephan ^a,b   Mertens, Patrick ^d   Quesada, Jean Louis ^f   Broussolle, Emmanuel ^d,e   Pollak, Pierre ^a,b,g   Thobois, Stéphane C ^d,e   Krack, Paul ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITÉ LYON 1   (France)

^e INSTITUT DES SCIENCES COGNITIVES   (France)

^f LABORATOIRE TIMC IMAG   (France)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; ANXIETY DISORDER; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACTIVITY; DRUG SENSITIZATION; EUPHORIA; FEMALE; HUMAN; MALE; MOTIVATION; MOTOR DYSFUNCTION; PARKINSON DISEASE; POSTOPERATIVE DEPRESSION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSTIMULANT EFFECT; SUBTHALAMUS;

EID: 84871227475     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302444     Document Type: Article

References (43)

1. Maricle RA, Nutt JG, Valentine RJ, et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995;45:1757-60.
2. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595-604. (Pubitemid 37162568)
3. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009;8:1140-9.
4. Lhommée E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviors. Brain 2012;135:1463-77.
5. Witjas T, Kaphan E, Régis J, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007;22:1729-34. (Pubitemid 47610462)
6. Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005;20:1052-5. (Pubitemid 41419526)
7. Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009;16:1148-52.
8. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-8. (Pubitemid 43673163)
9. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a (11C) raclopride PET study. Brain 2009;132:1376-85.
10. O'Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011;134:969-78.
11. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000;23(10 Suppl):S71-7.
12. Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010;9:1106-17.
13. Bejjani BP, Arnulf I, Demeret S, et al. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann Neurol 2000;47:655-8. (Pubitemid 30261904)
14. Moro E, Esselink RJ, Benabid AL, et al. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 2002;125:2408-17. (Pubitemid 35303501)
15. Piboolnurak P, Lang AE, Lozano AM, et al. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord 2007;22:990-7. (Pubitemid 46999296)
16. Thobois S, Ardouin C, Lhommée E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-27.
17. Haertzen CA. Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep 1966;18:163-94.
18. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003;18:524-30. (Pubitemid 36656536)
19. Ardouin C, Chéreau I, Llorca PM, et al. (Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease). Rev Neurol (Paris) 2009;165:845-56.
20. Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-97. (Pubitemid 26382973)
21. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-7. (Pubitemid 19008360)
22. Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:134-9.
23. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997;25:192-216. (Pubitemid 27501800)
24. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000;95(Suppl 2):S91-117.
25. Ungless MA, Whistler JL, Malenka RC, et al. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 2001;411:583-7. (Pubitemid 32531404)
26. Goto Y, Grace AA. Dopamine-dependent interactions between limbic and prefrontal cortical plasticity in the nucleus accumbens: disruption by cocaine sensitization. Neuron 2005;47:255-66. (Pubitemid 41019256)
27. Grace AA, Floresco SB, Goto Y, et al. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007;30:220-7. (Pubitemid 46654234)
28. Lodge DJ, Grace AA. Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. J Neurosci 2008;28:7876-82.
29. Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94:3363-7. (Pubitemid 27157317)
30. Conrad KL, Tseng KY, Uejima JL, et al. Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 2008;454:118-21. (Pubitemid 351931970)
31. Strakowski SM, Sax KW, Setters MJ, et al. Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry 1996;40:872-80. (Pubitemid 26356721)
32. Boileau I, Dagher A, Leyton M, et al. Modeling sensitization to stimulants in humans. Arch Gen Psychiatry 2006;63:1386-95.
33. Evans AH, Lawrence AD, Lees AJ. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:267-72.
34. Nutt JG, Carter JH, Lea ES, et al. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002;51:686-93. (Pubitemid 34568846)
35. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
36. Krack P, Fraix V, Mendes A, et al. Postoperative management of subthalamic nucleus stimulation for Parkinson' s disease. Mov Disord 2002;17(Suppl 3):S188-97. (Pubitemid 36040925)
37. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-34. (Pubitemid 37409709)
38. Witt K, Daniels C, Herzog J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2006;18:397-401.
39. Czernecki V, Pillon B, Houeto JL, et al. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson' s disease? J Neurol Neurosurg Psychiatry 2005;76:775-9. (Pubitemid 40805805)
40. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008;7:605-14.
41. Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51(Suppl 2):S25-9. (Pubitemid 28397140)
42. Kuoppamäki M, Al-Barghouthy G, Jackson M, et al. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Mov Disord 2002;17:1312-17.
43. Wu JC, Bell K, Najafi A, et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 1997;17:402-9. (Pubitemid 27499927)